Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

THE ROLE OF CYP1B1 IN THE RECURRENCE OF HEAD AND NECK CANCER

Award Number: F32CA144199
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 12/01/2010
PERIOD OF PERFORMANCE END DATE: 11/30/2013

Group Awards By:

View Award Description

THE ROLE OF CYP1B1 IN THE RECURRENCE OF HEAD AND NECK CANCER - DESCRIPTION (provided by applicant): Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most common type of cancer. Its incidence increased 60% recently in adults age 40 or less. Mortality among HNSCC patients is very high, often due to recurrence of primary disease. Major risk factors for HNSCC include tobacco and alcohol use. Data from this group and others suggest that estrogens may also contribute to the development of HNSCCs. The tobacco smoke carcinogen benzo(a)pyrene (B(a)P), ethanol from alcoholic drinks and the female hormone estrogen are all metabolized by cytochrome P450 (CYP) 1B1 to potentially carcinogenic metabolites. The hypothesis of the proposed studies is that a polymorphism in CYP1B1 (CYP1B1*2) confers a more aggressive disease phenotype and a greater risk of recurrence of HNSCC. Rationale for the role of CYP1B1 in HNSCC is provided by preliminary data that suggest that 1) the CYP1B1*2 polymorphism, which results in elevated basal expression of CYP1B1, confers increased risk of recurrence for HNSCC; 2) CYP1B1 protein is elevated in human HNSCCs as compared to non-neoplastic epithelium and 3) ethanol and estrogen induce CYP1B1 mRNA levels. In Aim 1, the effect of overexpressing a high-risk CYP1B1*2 allele vs wild type on selected biomarkers (cell proliferation, anchorage independence, invasion, survival, apoptosis and oxidative damage) will be evaluated in cultured premalignant oral leukoplakia (MSK-Leuki) cells following exposure to B(a)P, ethanol and estrogen. Results from studies in MSK-Leuki cells will be translated to an analysis of oral tissue from HNSCC patients in Aim 2. Patients with HNSCC will be genotyped for CYP1B1 (using TaqMan(R) assays) and the effect of the CYP1B1*2 allele on tumor recurrence will be examined in patients stratified by smoking, alcohol use and gender. Sections from tissue blocks from patients will be evaluated immunohistochemically for the level of biomarkers (apoptosis, proliferation and oxidative damage). The association of biomarker levels with CYP1B1 genotype will be investigated. The resulting data are anticipated to significantly enhance our understanding of the function of CYP1B1 in the recurrence of HNSCC and aid in determining the contribution of exposures to tobacco, estrogen and/or alcohol to recurrence in individuals carrying the high-risk CYP1Br2 allele. PUBLIC HEALTH RELEVANCE: Our findings suggest for the first time that a common polymorphism in the CYP1B1 gene increases risk of recurrence of HNSCC. Successful confirmation of this belief will greatly help us to more accurately predict who is at highest risk for recurrence of HNSCC, and aid in the development of new treatments and markers for the early detection and prevention of this devastating disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2013 ( Subtotal = $59,432 )
2013	2013	INSTITUTE FOR CANCER RESEARCH	333 Cottman Ave	Philadelphia	PA	19111	PHILADELPHIA	USA	Cancer Research Manpower	000	3	1/30/2013	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$59,432
														Subtotal = $59,432

Issue Date FY: 2012 ( Subtotal = $56,750 )
2012	2012	FOX CHASE CANCER CENTER	333 Cottman Ave	Philadelphia	PA	19111	PHILADELPHIA	USA	Cancer Research Manpower	000	2	11/29/2011	NON-COMPETING CONTINUATION	$56,750
														Subtotal = $56,750

Issue Date FY: 2010 ( Subtotal = $53,810 )
2010	2010	FOX CHASE CANCER CENTER	333 Cottman Ave	Philadelphia	PA	19111	PHILADELPHIA	USA	Cancer Research Manpower	000	1	9/27/2010	NEW	$53,810
														Subtotal = $53,810

Grand Total All Awards = $169,992

Top

All Categories

About

Search

Reports

Data Submission

Award Information

THE ROLE OF CYP1B1 IN THE RECURRENCE OF HEAD AND NECK CANCER

Award Number: F32CA144199

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 12/01/2010

PERIOD OF PERFORMANCE END DATE: 11/30/2013

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer